Lotus Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Lotus Pharmaceutical kazanç ve gelirinin sırasıyla yıllık 28.6% ve 15.5% oranında artması tahmin edilirken, EPS'nin yıllık 28.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

28.6%

Kazanç büyüme oranı

28.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	47.2%
Gelir büyüme oranı	15.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	03 Sep 2024

Gelecekteki son büyüme güncellemeleri

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14

Recent updates

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19

Kazanç ve Gelir Büyüme Tahminleri

TWSE:1795 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (TWD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	21,360	6,161	6,016	6,666	5
12/31/2024	18,492	4,771	4,312	6,365	4
6/30/2024	16,933	4,014	2,455	4,071	N/A
3/31/2024	16,632	3,948	1,717	3,325	N/A
12/31/2023	16,958	4,106	-1,661	1,614	N/A
9/30/2023	16,710	3,873	-918	3,440	N/A
6/30/2023	17,527	4,707	-1,211	2,974	N/A
3/31/2023	15,995	3,769	-894	3,251	N/A
12/31/2022	14,633	3,021	650	3,719	N/A
9/30/2022	14,264	3,105	181	2,198	N/A
6/30/2022	11,932	1,374	-227	2,012	N/A
3/31/2022	12,486	1,401	-1,892	496	N/A
12/31/2021	12,649	1,403	-1,496	120	N/A
9/30/2021	12,977	1,470	-1,029	421	N/A
6/30/2021	12,806	1,400	-1,182	26	N/A
3/31/2021	12,019	1,344	371	1,447	N/A
12/31/2020	10,729	1,027	-49	1,949	N/A
9/30/2020	10,802	848	-552	1,619	N/A
6/30/2020	9,933	769	-863	1,116	N/A
3/31/2020	9,307	519	-980	905	N/A
12/31/2019	9,611	663	-686	420	N/A
9/30/2019	8,130	596	-523	266	N/A
6/30/2019	7,693	463	1	691	N/A
3/31/2019	7,278	359	39	720	N/A
12/31/2018	6,429	99	403	797	N/A
9/30/2018	6,537	38	401	774	N/A
6/30/2018	6,535	19	277	657	N/A
3/31/2018	6,477	110	N/A	623	N/A
12/31/2017	6,424	22	N/A	591	N/A
9/30/2017	6,072	-171	N/A	696	N/A
6/30/2017	5,897	-252	N/A	965	N/A
3/31/2017	5,913	-270	N/A	1,186	N/A
12/31/2016	5,903	-134	N/A	1,233	N/A
9/30/2016	5,896	78	N/A	1,490	N/A
6/30/2016	5,910	126	N/A	1,378	N/A
3/31/2016	5,653	198	N/A	1,223	N/A
12/31/2015	5,522	104	N/A	1,078	N/A
9/30/2015	4,712	-102	N/A	436	N/A
6/30/2015	3,879	-204	N/A	-531	N/A
3/31/2015	3,125	-312	N/A	-886	N/A
12/31/2014	2,310	-442	N/A	-1,032	N/A
9/30/2014	2,201	-307	N/A	-1,310	N/A
6/30/2014	2,152	-269	N/A	-503	N/A
3/31/2014	2,411	-330	N/A	-379	N/A
12/31/2013	2,092	-143	N/A	-388	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1795 'nin tahmini kazanç büyümesi (yıllık 28.6% ) tasarruf oranının ( 1% ) üzerindedir.

Kazançlar ve Piyasa: 1795 şirketinin kazançlarının (yıllık 28.6% ) TW pazarından (yıllık 18.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1795 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 1795 şirketinin gelirinin (yıllık 15.5% ) TW pazarından (yıllık 12.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1795 şirketinin gelirinin (yıllık 15.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1795 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Lotus Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Price target increased by 17% to NT$390

Price target increased by 7.3% to NT$301

Price target increased by 7.5% to NT$300

Price target increased to NT$235

Consensus EPS estimates increase by 25%

Recent updates

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director

Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Wanida Boonpiraks as Representative of the Institutional Director

Lotus Pharmaceutical Co., Ltd. Announces the Resignation of Phannalin Mahawongtikul as Director

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

New minor risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 18%

Lotus Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of NT$4.65 per share

Lotus Pharmaceutical Co., Ltd. Announces Cash Dividend, Payable on August 30, 2024

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. (TWSE:1795) agreed to acquire Teva Pharma (Thailand) Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.

First quarter 2024 earnings: EPS misses analyst expectations

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Price target increased by 17% to NT$390

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Full year 2023 earnings: EPS exceeds analyst expectations

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Jun 13, 2024

Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024

Lotus Pharmaceutical Co., Ltd. Reaches Settlement Agreement with Novartis for Midostaurin Capsules in the USA

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Lotus Pharmaceutical Co., Ltd. Announces Director Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson

Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members

Upcoming dividend of NT$3.46 per share at 1.0% yield

Lotus Pharmaceutical Co., Ltd. Announces Board Changes

Investor sentiment improves as stock rises 25%

Price target increased by 7.3% to NT$301

Price target increased by 7.5% to NT$300

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Investor sentiment improves as stock rises 15%

Lotus Pharmaceutical Co., Ltd. Receives Tentative Approval for Its ANDA for Nintedanib Capsules, 100 Mg and 150 Mg, from the US FDA

Investor sentiment improved over the past week

Lotus Pharmaceutical Co., Ltd. Announces Executive Changes

Price target increased to NT$235

Consensus EPS estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lotus Pharmaceutical Co., Ltd. Receives the Final Approval for Its ANDA for Lenalidomide Capsules, 5 Mg, 10 Mg, 15 Mg and 25 Mg from the US FDA

Lotus Pharmaceutical Co., Ltd. Receives Tentative Approval for Midostaur in ANDA from the US FDA

Investor sentiment improved over the past week

Price target increased to NT$179

Price target increased to NT$173

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of NT$1.93 per share

Lotus Pharmaceutical Co., Ltd. Declares Cash Dividend, Payable on August 31, 2021

Lotus Pharmaceutical Co., Ltd. Announces Election of Directors

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to NT$162

Less than half of directors are independent

Lotus Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Lotus Pharmaceutical Co., Ltd. Announces Resignation of Hirofumi Imai as Director, Effective June 30, 2022

Investor sentiment improved over the past week

Consensus forecasts updated

Price target increased to NT$144

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$1.34 (vs NT$1.15 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS NT$1.38 (vs NT$1.23 in 2Q 2020)